Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
MWN-AI** Summary
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, reported its fourth quarter and full-year 2025 business updates and financial results on March 12, 2026. The company showcased encouraging early clinical activity for its lead candidate, ERAS-0015, during ongoing dose escalation studies. Prominent findings include confirmed partial responses in various RAS-mutant tumors, demonstrating favorable safety and tolerability with low-grade adverse events and linear pharmacokinetics. The company anticipates releasing Phase 1 monotherapy data for ERAS-0015 in the first half of 2026 and for ERAS-4001 in the second half.
Erasca has strengthened its financial position by successfully completing a $259 million upsized public offering in January 2026, resulting in a pro forma cash, cash equivalents, and marketable securities balance of $434 million, expected to fund operations into the second half of 2028. For the fourth quarter ended December 31, 2025, Erasca reported a net loss of $29.1 million, slightly down from $32.2 million a year earlier, with full-year losses of $124.5 million compared to $161.7 million in 2024.
Furthermore, Erasca expanded its licensing agreement for ERAS-0015 to include China, Hong Kong, and Macau, increasing its global rights for this promising therapy. The company also received critical U.S. patents that protect the compositions of its RAS-targeting franchise through 2043.
Looking ahead, notable milestones include the initiation of expansion cohorts for the AURORAS-1 trial and the Phase 1 data readouts for both ERAS-0015 and ERAS-4001 planned for 2026. With a focus on executing its clinical programs efficiently, Erasca aims to drive innovation within the oncology landscape targeting RAS/MAPK pathway-driven cancers.
MWN-AI** Analysis
Erasca, Inc. (Nasdaq: ERAS) recently reported encouraging clinical data and a strong financial position following its fourth-quarter 2025 and full-year results. The positive early clinical activity seen with ERAS-0015, particularly the confirmed partial responses across various RAS-mutant tumors, positions the company favorably within the oncology landscape. As its RAS-targeting franchise progresses into the next stages of development, the anticipated Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 expected in 2026 could serve as significant catalysts, attracting investor attention.
Erasca's robust balance sheet, with approximately $434 million post financing, provides a clear runway for operations well into 2028. This financial strength mitigates risks associated with funding clinical trials and research, allowing the company to execute its operational plans without immediate capital concerns.
Moreover, the recent expansion of the licensing agreement to include key territories such as China, Hong Kong, and Macau enhances Erasca's commercial prospects and market reach. The protection offered by newly issued U.S. patents for its RAS-Targeting Franchise further solidifies its competitive advantage, offering a layer of security for its future revenue streams.
Despite a net loss of $124.5 million in 2025, the reduction in R&D expenses—illustrating cost management—signals a focus on streamlined execution. This strategic prudence, coupled with the positive clinical data, creates a compelling narrative for investors.
In summary, potential investors should consider Erasca as a promising opportunity in the oncology sector, particularly with the anticipated data releases and continued development of its innovative therapies. However, as always, due diligence is crucial, weighing potential risks against the exciting growth prospects ahead.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics
Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026
Successfully completed $259 million upsized financing in January
Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2025.
“Our RAS-targeting franchise continues to advance rapidly in the clinic, reflecting our strong operational execution and high investigator and patient enthusiasm,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Importantly, the best-in-class potential of our pan-RAS molecular glue ERAS-0015 was underscored by ongoing partial responses at a low dose of 8 mg QD across multiple tumor types and RAS mutations, together with favorable safety and pharmacokinetics (PK) data, as of the data cutoff*. This clinical progress and the successful upsized public offering heighten excitement in our RAS-targeting franchise and strengthen our financial position as we further advance clinical development.”
Dr. Lim continued, “In 2026, we expect additional Phase 1 data for ERAS-0015 in the first half of the year, as well as initial data for our pan-KRAS inhibitor ERAS-4001 in the second half of the year. Our focus continues to be on streamlined execution across our clinical programs, and with our recent capital infusion, we believe that we are strongly positioned to drive our RAS-targeting franchise for the benefit of patients.”
Research and Development (R&D) Highlights
- Announced Promising Early Clinical Data for ERAS-0015: In January 2026, Erasca announced promising early clinical activity for ERAS-0015 during dose escalation, including confirmed partial responses in multiple tumor types with different RAS mutations, favorable safety and tolerability data, with no dose-limiting toxicities and predominantly low-grade adverse events and encouraging safety and well-behaved, linear PK.*
* Data cutoff date was January 7, 2026
Corporate Highlights
- Expanded License Agreement Territory for ERAS-0015: In March 2026, Erasca announced the expansion of its existing licensing agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, providing Erasca with worldwide rights to its potential best-in-class pan-RAS molecular glue ERAS-0015.
- Completed Upsized Financing: In January 2026, Erasca completed a successful upsized public offering, raising approximately $258.8 million in gross proceeds. The transaction, supported by new and existing healthcare-focused investors, significantly strengthened Erasca’s balance sheet.
- Composition of Matter Patents Issued in the U.S. for RAS-Targeting Franchise: Erasca announced that the U.S. Patent and Trademark Office issued patents for its RAS-Targeting Franchise
- U.S. patent No. 12,552,813 titled “Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof,” was issued in February 2026, which protects the composition of matter of ERAS-4001 and related compositions until June 2043, which period may be subject to patent term adjustments or extensions
- U.S. patent No. 12,458,647 titled “Macrocyclic Derivative And Use Thereof,” was issued in October 2025, which protects the composition of matter of ERAS-0015 and related compositions until September 2043, which period may be subject to patent term adjustments or extensions
Key Upcoming Milestones
- AURORAS-1 and JYP0015M101**: Phase 1 trials for ERAS-0015 (pan-RAS molecular glue) in patients with RAS-mutant solid tumors in the US and China, respectively
- Phase 1 monotherapy data from both the US and China expected in the first half of 2026
- Initiation of AURORAS-1 monotherapy expansion cohorts and combination dose escalation cohort planned for the second half of 2026
- AURORAS-1 monotherapy expansion data and combination dose escalation data planned for 2027
- BOREALIS-1: Phase 1 trial for ERAS-4001 (pan-KRAS inhibitor) in patients with KRAS-mutant solid tumors
- Phase 1 monotherapy data expected in the second half of 2026
- Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
** JYP0015M101 is a clinical trial in China sponsored by Joyo that is assessing ERAS-0015 in adult patients with advanced solid tumors harboring specific RAS mutations.
Fourth Quarter and Full Year 2025 Financial Results
Cash Position: Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, compared to $440.5 million as of December 31, 2024. Erasca expects its current cash, cash equivalents, and marketable securities (inclusive of the net proceeds received from the January 2026 underwritten offering and net of the payment to Joyo in connection with the exercise of the option to obtain worldwide rights) to fund operations into the second half of 2028.
Research and Development (R&D) Expenses: R&D expenses were $23.2 million for the quarter ended December 31, 2025, compared to $26.1 million for the quarter ended December 31, 2024. The decrease was primarily driven by decreases in expenses incurred in connection with clinical trials, preclinical studies, discovery activities, outsourced services, and consulting fees. R&D expenses were $92.9 million for the full year ended December 31, 2025, compared to $115.4 million for the full year ended December 31, 2024. Erasca also recorded $9.5 million of in-process R&D expense during the year ended December 31, 2025 for the achievement of milestones under Erasca’s ERAS-0015 and ERAS-4001 license agreements and $22.5 million of in-process R&D expense during the year ended December 31, 2024 for upfront payments under Erasca’s ERAS-0015 and ERAS-4001 license agreements.
General and Administrative (G&A) Expenses: G&A expenses were $9.4 million for the quarter ended December 31, 2025, compared to $9.6 million for the quarter ended December 31, 2024. The decrease was primarily driven by a decrease in legal fees. G&A expenses were $38.6 million for the full year ended December 31, 2025, compared to $41.7 million for the full year ended December 31, 2024.
Net Loss: Net loss was $29.1 million, or $(0.10) per basic and diluted share, for the quarter ended December 31, 2025, compared to $32.2 million, or $(0.11) per basic and diluted share, for the quarter ended December 31, 2024. For the full year ended December 31, 2025, Erasca reported a net loss of $124.5 million, or $(0.44) per basic and diluted share, compared to a net loss of $161.7 million, or $(0.69) per basic and diluted share, for the full year ended December 31, 2024.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-0015 and ERAS-4001, and the planned advancement of our development pipeline, including the anticipated timing of data readouts for the AURORAS-1 and JYP0015M101 trials, and the BOREALIS-1 trial, and the anticipated timing of the initiation of additional expansion cohorts for the AURORAS-1 and BOREALIS-1 trials; our belief that we are strongly positioned to drive our RAS-targeting franchise for the benefit of patients; the sufficiency of our cash, cash equivalents, and marketable securities to fund our operations into the second half of 2028; and statements relating to the protections provided by our intellectual property portfolio, including the issuance of patents, the anticipated periods of time until such patents expire, and the related implications for us. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that an unconfirmed partial response to treatment may not ultimately result in a confirmed partial response to treatment after follow-up evaluations; any forward-looking statements regarding dose-response relationships reflect current expectations and/or assumptions, and are subject to risks and uncertainties that could cause actual results to differ materially; our assumptions about the development potential of ERAS-0015 and ERAS-4001 are based in large part on the preclinical data generated by the licensors and we may observe materially and adversely different results as we conduct our planned studies and trials; the initial data presented from the JYP0015M101 trial will be based upon data generated by the licensor; results from preclinical studies or early clinical trials not necessarily being predictive of future results; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; potential delays in the commencement, enrollment, data readout, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; the inability to realize any benefits from our current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Erasca, Inc.
Selected Consolidated Balance Sheet Data
(In thousands)
(Unaudited)
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Balance Sheet Data: | ||||||||
| Cash, cash equivalents, and marketable securities | $ | 341,796 | $ | 440,473 | ||||
| Working capital | 257,728 | 277,398 | ||||||
| Total assets | 396,154 | 502,526 | ||||||
| Accumulated deficit | (892,209) | (767,663) | ||||||
| Total stockholders’ equity | 325,171 | 423,499 |
Erasca, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 23,241 | $ | 26,122 | $ | 92,854 | $ | 115,359 | ||||||||
| In-process research and development | — | — | 9,500 | 22,500 | ||||||||||||
| General and administrative | 9,363 | 9,590 | 38,551 | 41,728 | ||||||||||||
| Total operating expenses | 32,604 | 35,712 | 140,905 | 179,587 | ||||||||||||
| Loss from operations | (32,604) | (35,712) | (140,905) | (179,587) | ||||||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 3,566 | 5,283 | 16,607 | 20,093 | ||||||||||||
| Other expense, net | (54) | (1,803) | (248) | (2,156) | ||||||||||||
| Total other income (expense), net | 3,512 | 3,480 | 16,359 | 17,937 | ||||||||||||
| Net loss | $ | (29,092) | $ | (32,232) | $ | (124,546) | $ | (161,650) | ||||||||
| Net loss per share, basic and diluted | $ | (0.10) | $ | (0.11) | $ | (0.44) | $ | (0.69) | ||||||||
| Weighted-average shares of common stock used in computing net loss per share, basic and diluted | 283,829,318 | 282,845,918 | 283,533,696 | 233,817,916 | ||||||||||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized (loss) gain on marketable securities, net | (21) | (1,420) | 223 | 328 | ||||||||||||
| Comprehensive loss | $ | (29,113) | $ | (33,652) | $ | (124,323) | $ | (161,322) |
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ**
What specific factors contributed to the encouraging early clinical activity observed during the ERAS-00dose escalation in Erasca Inc. ERAS, particularly in RAS-mutant tumors?
How does the favorable safety and tolerability profile of ERAS-0015 impact future clinical trials and potential market approval for Erasca Inc. ERAS?
What insights can we expect from the upcoming Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 in 2026, and how will it influence Erasca Inc. ERAS's development strategy?
With a robust financial position post-financing, how does Erasca Inc. ERAS plan to allocate its resources to maximize the development and commercial potential of its RAS-targeting franchise?
**MWN-AI FAQ is based on asking OpenAI questions about Erasca Inc. (NASDAQ: ERAS).
NASDAQ: ERAS
ERAS Trading
-4.65% G/L:
$14.97 Last:
966,939 Volume:
$15.12 Open:
